Literature DB >> 25316894

Should Patients With COPD Be Vaccinated?

Pinar Cimen1, Mehmet Unlu2, Cenk Kirakli1, Nuran Katgi1, Fatma Demirci Ucsular1, Aysu Ayranci1, Salih Zeki Guclu1.   

Abstract

BACKGROUND: Exacerbations of COPD are a major component of the socioeconomic burden related to COPD, and frequent exacerbations are associated with greater decline in health status. Tracheobronchial infections are involved in 50-70% of exacerbations, so influenza and pneumococcal vaccines are recommended for prevention. The aim of this study was to determine the level of knowledge among COPD patients about the vaccines, find the rate of patients inoculated with both influenza and pneumococcal vaccines, and assess the effectiveness of vaccination status.
METHODS: Patients with COPD were recruited from the out-patient clinic of our hospital between September and October 2012. Subject demographic data such as age, gender, level of education, and smoking status were recorded. Vaccination status, number of subjects who were informed by a health-care professional about immunization, and COPD-related emergency or hospital admissions triggered by tracheobronchial infections over 1 y after administration of both influenza and pneumococcal vaccines were noted.
RESULTS: Eighty-eight subjects were enrolled during the study period. Eighty-two subjects were male (93.2%), 6 subjects were female (6.8%), and the median age was 61.5 y. According to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2006 classification, 5 subjects were in stage 1 (5.7%), 22 subjects were in stage 2 (25%), 34 subjects were in stage 3 (38.6%), and 27 subjects were in stage 4 (30.7%). Sixty-two subjects had graduated from primary school (70.5%), 21 subjects had graduated from high school (23.9%), one subject had graduated from university (1.1%), and 4 subjects had no education (4.5%). Forty-five subjects (51%) were vaccinated. There was no significant correlation between level of education and vaccination status (P=.37). Both COPD-related emergency department and hospital visits were significantly decreased in vaccinated patients with COPD (P<.001 and P=.02, respectively). Of all the subjects, 39.7% (35 of 88 subjects) mentioned that no health-care professional recommended vaccination.
CONCLUSIONS: Physicians should be more aware of vaccination and recommend both influenza and pneumococcal vaccines to all patients with COPD to reduce exacerbations.
Copyright © 2015 by Daedalus Enterprises.

Entities:  

Keywords:  COPD; chronic obstructive pulmonary disease; immunization; influenza vaccination; pneumococcal vaccination

Mesh:

Year:  2014        PMID: 25316894     DOI: 10.4187/respcare.03350

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  12 in total

1.  Influenza and pneumonia vaccination rates in patients hospitalized with acute respiratory failure.

Authors:  Ipek Candemir; Sema Turk; Pinar Ergun; Dicle Kaymaz
Journal:  Hum Vaccin Immunother       Date:  2019-06-03       Impact factor: 3.452

Review 2.  [Knowledge Structure of Chronic Obstructive Pulmonary Disease Health Information on Health-Related Websites and Patients' Needs in the Literature Using Text Network Analysis].

Authors:  Ja Yun Choi; Su Yeon Lim; So Young Yun
Journal:  J Korean Acad Nurs       Date:  2021-12       Impact factor: 0.984

3.  Factors Affecting Influenza Vaccination Rates among Patients with Chronic Obstructive Pulmonary Disease in Rize, Turkey.

Authors:  Songül Özyurt; Bilge Yılmaz Kara; Neslihan Özçelik; Ünal Şahin
Journal:  Turk Thorac J       Date:  2018-06-12

Review 4.  Improving outcomes in chronic obstructive pulmonary disease: the role of the interprofessional approach.

Authors:  Bravein Amalakuhan; Sandra G Adams
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-06-26

5.  Influenza and Pneumonia Vaccination Rates and Factors Affecting Vaccination among Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Ülkü Aka Aktürk; Aslı Görek Dilektaşlı; Aysun Şengül; Banu Musaffa Salepçi; Nuray Oktay; Mustafa Düger; Hale Arık Taşyıkan; Nagihan Durmuş Koçak
Journal:  Balkan Med J       Date:  2017-04-06       Impact factor: 2.021

6.  Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD.

Authors:  Chih-Cheng Lai; Ya-Hui Wang; Cheng-Yi Wang; Hao-Chien Wang; Chong-Jen Yu; Likwang Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-03-08

Review 7.  The full benefits of adult pneumococcal vaccination: A systematic review.

Authors:  Elizabeth T Cafiero-Fonseca; Andrew Stawasz; Sydney T Johnson; Reiko Sato; David E Bloom
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

8.  Overview of pneumococcal serotypes and genotypes causing diseases in patients with chronic obstructive pulmonary disease in a Spanish hospital between 2013 and 2016.

Authors:  Hisashi Shoji; Daniel A Vázquez-Sánchez; Aida Gonzalez-Diaz; Meritxell Cubero; Fe Tubau; Salud Santos; Dolores García-Somoza; Josefina Liñares; José Yuste; Sara Martí; Carmen Ardanuy
Journal:  Infect Drug Resist       Date:  2018-09-04       Impact factor: 4.003

9.  Evaluation of the primary care for chronic diseases in the high coverage context of the Family Health Strategy.

Authors:  Kelly Cristina Gomes Alves; Rafael Alves Guimarães; Marta Rovery de Souza; Otaliba Libânio de Morais Neto
Journal:  BMC Health Serv Res       Date:  2019-11-29       Impact factor: 2.655

10.  Oscillococcinum® for upper respiratory tract infections and exacerbations in COPD: an observational, prospective study (OXITUNIS).

Authors:  Hichem Aouina; Anis Bamri; Aurélien Vesin; Karine Danno; Eléonore Aubry; Cécile Faure; Naoual Boujedaini
Journal:  Drugs Context       Date:  2021-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.